Skip to content
Search

Latest Stories

British financial services achieve third quarter of growth, survey says

British financial services achieve third quarter of growth, survey says

BRITAIN'S financial services grew for the third quarter in a row in the last three months of 2021 and at their fastest pace since mid-2017, even though Covid-19 dampened optimism, a survey of 105 firms in the sector showed.

A year since the Brexit transition period ended, the health of British financial services is being closely monitored after the city of London was largely cut off from the European Union.


"While volumes and profitability growth across the financial services sector remain buoyant, the softening in optimism is something to watch closely, due to increased Covid-19 uncertainty clouding the near-term economic outlook," CBI chief economist Rain Newton-Smith said in statement.

The survey of 105 financial firms by the CBI employers group and consultants PwC was completed just before fresh restrictions were introduced in Britain last month to tackle spiralling cases of the Omicron variant of coronavirus.

In the first three months of 2022, firms expect activity to remain robust and at a strong pace, the survey found.

Profitability growth is expected to ease somewhat in the coming months, with numbers employed predicted to grow solidly and retaining talent the top workforce priority, it said.

Looking just beyond the first quarter, Britain has said that large companies must disclose climate-related financial data from April 2022 using a globally-agreed set of guidance.

The survey showed that 40 per cent of firms were "somewhat prepared" for April, with 14 per cent saying there were not ready, and remaining companies saying they were fairly or very prepared.

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less